IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®

Wed, 29 Jul 2026 08:25:00 -0400

The petition by The Society of Interventional Oncology (SIO) includes adding criteria for patients aged 50-69 who are poor surgical candidates or who decline surgery in the National Comprehensive Cancer Network (NCCN) treatment guidelines, expanding the current eligible population of patients aged 70 and above

CAESAREA, Israel, July 29, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that the

IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®

Wed, 29 Jul 2026 08:25:00 -0400

IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®

Wed, 29 Jul 2026 08:25:00 -0400

IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®

Wed, 29 Jul 2026 08:25:00 -0400

IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®

Wed, 29 Jul 2026 08:25:00 -0400

IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®

Wed, 29 Jul 2026 08:25:00 -0400

IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®

Wed, 29 Jul 2026 08:25:00 -0400

IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®

Wed, 29 Jul 2026 08:25:00 -0400

IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site

Mon, 27 Jul 2026 08:32:00 -0400

Company signed agreement with the West Cancer Center & Research Institute, the first clinical site for its post-marketing study for ProSense® cryoablation in the treatment of low-risk breast cancer

CAESAREA, Israel, July 27, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that the West Cancer Center & Research Institute in Germantown, Tennessee will serve as the first

IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site

Mon, 27 Jul 2026 08:32:00 -0400

IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site

Mon, 27 Jul 2026 08:32:00 -0400

IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site

Mon, 27 Jul 2026 08:32:00 -0400

IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site

Mon, 27 Jul 2026 08:32:00 -0400

IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site

Mon, 27 Jul 2026 08:32:00 -0400

IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site

Mon, 27 Jul 2026 08:32:00 -0400

IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site

Mon, 27 Jul 2026 08:32:00 -0400

IceCure Medical expands U.S. sales team after 70% install base growth

Tue, 14 Jul 2026 08:33:26 -0400

IceCure Medical Ltd. (Nasdaq: ICCM) has expanded its U.S. sales and marketing teams, adding personnel in New York, Southern California, and the Midwest, along with additional clinical support staff, according to a press release dated July 14, 2026.

The expansion follows a previously reported 70% growth in the company's active U.S. commercial install base for its ProSense® cryoablation system, which the company attributed to FDA marketing authorization received in October 2025, clinical guidelines, and physician demand.

ProSense® is a liquid nitrogen-based cryoablation system used to destroy tumors by freezing. Procedures are now being performed in Los Angeles, New York, Atlanta, Dallas, Detroit,

IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation